1998
Life Sciences
Medical Devices
Development of PEG-Uricase for Treatment of Intractable Gout and
Mountain View Pharmaceuticals, Inc.
Menlo Park (California)
Savient Pharmaceuticals Inc. (Formerly: Bio-Technology General Ltd.)
Rehovot (Tel Aviv & Central)
Project description
The U.S. Food and Drug Administration has approved KRYSTEXXA(TM) (pegloticase), a PEGylated uric acid specific enzyme indicated for the treatment…
Read More
The U.S. Food and Drug Administration has approved KRYSTEXXA(TM) (pegloticase), a PEGylated uric acid specific enzyme indicated for the treatment of chronic gout in adult patients that are refractory to conventional therapy. The drug was developed by Mountain View Pharmaceuticals, and Bio-technology General (acquired by Ferring Pharmaceuticals in 2005) with a grant from the BIRD Foundation
Read Less#875